Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency
Status:
Terminated
Trial end date:
2020-09-02
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the efficacy of pamiparib in participants with metastatic
castration-resistant prostate cancer (mCRPC) positive for circulating tumor cells (CTC) with
homologous recombination deficiency (CTC-HRD). All participants will receive pamiparib. The
purpose of this study is to demonstrate that pamiparib will improve Objective Response Rate
(ORR) and Prostate-Specific Antigen (PSA) response rate